- Stocks
- Healthcare
- NASDAQ: RVMD

Price (delayed)

$29.99

Market cap

$2.21B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.07

Enterprise value

$2.04B

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities

The debt has contracted by 4.3% YoY

The company's equity has surged by 90% YoY but it fell by 5% QoQ

RVMD's quick ratio has surged by 87% year-on-year but it is down by 9% since the previous quarter

Revolution Medicines's net income has plunged by 93% YoY and by 14% from the previous quarter

The revenue has declined by 13% year-on-year and by 3.2% since the previous quarter

What are the main financial stats of RVMD

Market
Valuations
Earnings

Shares outstanding

73.58M

Market cap

$2.21B

Enterprise value

$2.04B

Price to earnings (P/E)

N/A

Price to book (P/B)

3.22

Price to sales (P/S)

54.7

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

50.76

Revenue

$40.24M

EBIT

-$142.5M

EBITDA

-$135.65M

Free cash flow

-$130.13M

Per share
Balance sheet
Liquidity

EPS

-$2.07

Free cash flow per share

-$1.77

Book value per share

$9.33

Revenue per share

$0.55

TBVPS

$9.52

Total assets

$774.05M

Total liabilities

$89.04M

Debt

$32.49M

Equity

$685.01M

Working capital

$615.21M

Debt to equity

0.05

Current ratio

14.43

Quick ratio

14.28

Net debt/EBITDA

1.21

Margins
Efficiency
Dividend

EBITDA margin

-337.1%

Gross margin

100%

Net margin

-355.1%

Operating margin

-356.8%

Return on assets

-20.8%

Return on equity

-23.9%

Return on invested capital

-34%

Return on capital employed

-19.6%

Return on sales

-354.1%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Revolution Medicines stock price performed over time

Intraday

0.71%

1 week

-6.43%

1 month

5.19%

1 year

-11.46%

YTD

-24.25%

QTD

-5.51%

How have Revolution Medicines's revenue and profit performed over time

Revenue

$40.24M

Gross profit

$40.24M

Operating income

-$143.56M

Net income

-$142.9M

Gross margin

100%

Net margin

-355.1%

The net margin has plunged by 121% YoY and by 17% from the previous quarter

Revolution Medicines's operating margin has plunged by 100% YoY and by 17% from the previous quarter

Revolution Medicines's net income has plunged by 93% YoY and by 14% from the previous quarter

RVMD's operating income has dropped by 75% year-on-year and by 13% since the previous quarter

What is Revolution Medicines's growth rate over time

What is Revolution Medicines stock price valuation

P/E

N/A

P/B

3.22

P/S

54.7

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

50.76

The EPS has surged by 85% year-on-year but it has declined by 7% since the previous quarter

The company's equity has surged by 90% YoY but it fell by 5% QoQ

The P/B is 29% lower than the last 4 quarters average of 4.5

The revenue has declined by 13% year-on-year and by 3.2% since the previous quarter

The stock's price to sales (P/S) is 7% less than its last 4 quarters average of 58.7

How efficient is Revolution Medicines business performance

The return on sales has dropped by 106% year-on-year and by 17% since the previous quarter

Revolution Medicines's return on equity has surged by 68% YoY and by 2% QoQ

RVMD's ROIC is up by 26% year-on-year but it is down by 3.7% since the previous quarter

RVMD's ROA is up by 16% YoY

What is RVMD's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for RVMD.

How did Revolution Medicines financials performed over time

RVMD's quick ratio has surged by 87% year-on-year but it is down by 9% since the previous quarter

Revolution Medicines's current ratio has soared by 85% YoY but it has decreased by 9% from the previous quarter

The debt is 95% less than the equity

The company's equity has surged by 90% YoY but it fell by 5% QoQ

The debt to equity has contracted by 44% YoY but it has grown by 25% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.